Clinical trials for Squamous cell carcinoma of the oropharynx
41 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT06915038ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the OropharynxIndiana University · PI: Michael Sim, MD
- RECRUITINGPhase 1NCT06747390Intratumoral Lidocaine Injection Before Oropharyngeal Cancer SurgeryRyan Carey · PI: Ryan Carey, MD
- RECRUITINGPhase 2NCT06702033The Minimalist Trial-2Washington University School of Medicine · PI: Douglas Adkins, M.D.
- RECRUITINGPhase 1NCT06589609Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal CancerBlueSky Immunotherapies GmbH
- RECRUITINGPhase 2NCT06223568Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerNational Cancer Institute (NCI) · PI: Clint T Allen, M.D.
- RECRUITINGPhase 2NCT05582122SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal CancersUNICANCER
- ACTIVE NOT RECRUITINGNCT06592716Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?Rigshospitalet, Denmark · PI: Christian von Buchwald, Professor, MD, DMSci
- RECRUITINGPhase 2NCT06323460Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerOhio State University Comprehensive Cancer Center · PI: Sujith Baliga
- RECRUITINGPhase 2NCT06088381Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)University of Maryland, Baltimore · PI: Jason K Molitoris, MD, PhD
- RECRUITINGN/ANCT06061705Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to ImmunotherapiesFondation Hôpital Saint-Joseph · PI: Eric Raymond, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05996523Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerNational Cancer Institute (NCI) · PI: Charalampos Floudas, M.D.
- RECRUITINGNCT05862792Liposomal Bupivacaine and Transoral Robotic SurgeryGeisinger Clinic
- RECRUITINGNCT05649865Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)Region Skane · PI: Johanna Sjövall, MD,PhD
- ACTIVE NOT RECRUITINGNCT05814549A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)Memorial Sloan Kettering Cancer Center · PI: Nancy Lee, MD
- RECRUITINGNCT05522881The Registry Study of Genetic Alterations of Oropharyngeal Cancer in TaiwanNational Health Research Institutes, Taiwan · PI: Pei-Jen Lou, MD, PhD
- RECRUITINGNCT05600842De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the OropharynxUniversity of California, Irvine · PI: Eric Chen, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05387915Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal CancerEmory University · PI: James E Bates, MD
- RECRUITINGN/ANCT05278039Training Swallowing Initiation During ExpirationNorthwestern University · PI: Bonnie Martin-Harris, PhD
- ACTIVE NOT RECRUITINGN/ANCT05119036Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell CarcinomaIndiana University · PI: Michael Sim, MD
- RECRUITINGNCT05918510Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma VirusRegina Elena Cancer Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04708470A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon CancersNational Cancer Institute (NCI) · PI: Hoyoung M Maeng, M.D.
- ACTIVE NOT RECRUITINGN/ANCT05048459Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of DiseaseMemorial Sloan Kettering Cancer Center · PI: Nancy Lee, MD
- RECRUITINGPhase 2NCT04900623Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT StudyJonathan Schoenfeld, MD, MPH · PI: Jonathan D Schoenfeld, MD, MPH
- ACTIVE NOT RECRUITINGPhase 2NCT04502407Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal CancerCedars-Sinai Medical Center · PI: Zachary S Zumsteg, MD
- RECRUITINGN/ANCT04104945p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)AHS Cancer Control Alberta · PI: Harvey Quon, MD
- ACTIVE NOT RECRUITINGNCT05904327Circulating Biomarkers in Oropharyngeal CancersRegion Örebro County · PI: Gisela Helenius
- RECRUITINGNCT04564989Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCCUNC Lineberger Comprehensive Cancer Center · PI: Wendell Yarbrough, MD
- ACTIVE NOT RECRUITINGNCT04965792Post-treatment Surveillance in HPV+ Oropharyngeal SCCDana-Farber Cancer Institute · PI: Eleni M Rettig, MD
- RECRUITINGPhase 2NCT04444869Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal CancerUniversity of Missouri-Columbia · PI: Gregory Biedermann, MD
- RECRUITINGPhase 2NCT04220749Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell CarcinomaLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · PI: Danielle MacNeil, M.D.
- ACTIVE NOT RECRUITINGNCT04151134Evaluation of Tongue Base MucOsectomy & Step sErial SectioningRoyal Marsden NHS Foundation Trust
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03952585De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerNational Cancer Institute (NCI) · PI: Sue S Yom
- ACTIVE NOT RECRUITINGN/ANCT04124198Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell CarcinomaChristian von Buchwald · PI: Christian von Buchwald, MD, DMSc.
- ACTIVE NOT RECRUITINGPhase 2NCT03621696Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"Washington University School of Medicine · PI: Douglas Adkins, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT03646461Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCUniversity of California, San Diego · PI: Kathryn Gold, MD
- ACTIVE NOT RECRUITINGN/ANCT03729518TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the NeckAbramson Cancer Center at Penn Medicine
- RECRUITINGNCT04224389IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell CarcinomasGustave Roussy, Cancer Campus, Grand Paris
- ACTIVE NOT RECRUITINGN/ANCT03210103Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal CancerLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · PI: David Palma
- ACTIVE NOT RECRUITINGPhase 2NCT03224000Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal CancerM.D. Anderson Cancer Center · PI: Clifton Fuller, MD, PHD
- ACTIVE NOT RECRUITINGN/ANCT02984410Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal CarcinomaEuropean Organisation for Research and Treatment of Cancer - EORTC · PI: Christian Simon
- ACTIVE NOT RECRUITINGPhase 2NCT01898494Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal CancerECOG-ACRIN Cancer Research Group · PI: Robert Ferris